• Patients with histologically proven untreated peripheral T-cell lymphoma (include PTCL not otherwise specified, angioimmunoblastic T cell lymphoma, anaplastic large cell lymphoma, enteropathy-associated T cell lymphoma, Monomorphic epitheliotropic intestinal T-cell lymphoma, Nodal peripheral T-cell lymphoma with T-follicular helper phenotype and Follicular T-cell lymphoma).

• Males and females of 18 years of age to 80 years of age.

• Patients have not received anti-tumor therapy.

• Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2.

• Fit chemotherapy indications and basic requirements, including no obvious abnormal function of heart, liver, lung and kidney: creatine ≤2.0×ULN, total bilirubin ≤2.0mg/dl, transaminases≤3×ULN.

• Normal peripheral hemogram: absolute neutrophil count(ANC)≥1.5×10\^9/L, hemoglobin(Hb)≥90g/L, platelet(PLT)≥100×10\^12/L.

• None of other serious disease conflict with the therapeutic regimen.

• None of other malignant tumor.

• Pregnancy test of women at reproductive age must be negative.

⁃ Estimated survival time ≥ 3 months with good compliance.

⁃ Voluntary participation, cooperate with the experimental observation, and sign a written informed consent.